A January 2026 BMJ meta-analysis of 9,341 adults across 37 studies found that once patients stop GLP-1 medications, blood pressure, glucose, and lipid markers are all projected to return to pre-treatment baseline within about 1.4 to 1.5 years.[1] This data raises an important question
Compounded products do not undergo the same FDA manufacturing review as brand products and may differ in strength, vehicle, combinations, and quality controls, with quality varying by pharmacy
Diet aids like Alli only offer modest weight loss and come with side effects
In addition to their potent metabolic actions that reduce hyperglycaemia and body weight, GLP-1RAs also lower the risk of major kidney, cardiovascular and mortality outcomes across broad populations with cardiovascular disease or CKD, with and without diabetes or obesity
Author Contributions Kayla Parsons: writing original draft (lead), writing review and editing (equal)